Document:

Amendment to Clinical Development and License Agreement

 Exhibit 10.1 
 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF

 DENOTED WITH “***” 
 AMENDMENT 
 TO 

CLINICAL DEVELOPMENT AND LICENSE AGREEMENT 
 This Amendment (this “Amendment”) to the Clinical Development and License Agreement, dated as of July 14, 2005, as amended on February 15, 2006, May 16,
2006, August 2, 2006, March 12, 2007, September 5, 2007, January 2, 2009, May 26, 2010 and October 4, 2010 (as amended from time to time, the “CDC License”), is dated as of
May 12, 2011, by and among CDC V, LLC (“CDC”), NB Athyrium LLC, a Delaware limited liability company (“Athyrium”), BioDelivery Sciences International, Inc. (“BioDelivery”), Arius Pharmaceuticals,
Inc., a wholly-owned subsidiary of BioDelivery (“Arius”) and Arius Two, Inc., a wholly-owned subsidiary of BioDelivery (“Arius Two” and together with Arius and BioDelivery, collectively, the
“Company”). Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the CDC License. 
 RECITALS 
 WHEREAS, CDC (as successor in interest to CDC IV, LLC),
BioDelivery, Arius and Arius Two entered into the CDC License, pursuant to which, among other things, CDC invested in the development of certain compounds being developed by the Company; and 

WHEREAS, CDC and Athyrium entered into that certain Royalty Sale Agreement dated December 22, 2009, pursuant to which Athyrium
acquired certain royalties and other rights under the CDC License, including the right to consent to certain amendments to the CDC License; and 
 WHEREAS, Company, CDC and Athyrium desire to resolve certain disputes concerning adjustments to the royalty rate owed to CDC and Athyrium under the CDC License for sales of Product; and 

WHEREAS, CDC, Athyrium and the Company desire to amend the CDC License as set forth in this Amendment. 

NOW THEREFORE, in consideration of the mutual covenants herein, and intending to be legally bound hereby, the parties agree as follows:

 1. The CDC License is hereby amended as follows: 
 (a) Amended Definitions. The following defined terms set forth in Article 1 of the CDC License shall be amended and restated in their entirety to read as follows: 

“Competing Product” means any transmucosal formulation of fentanyl, other than a Product, which has obtained
Approval in an indication for the treatment of break through cancer pain management; provided, however, that a Competing Product shall not include a generic formulation of ACTIQ®, sugar-free ACTIQ®, or
OraVescent®. 

 “Product” means any product that contains the Compound either alone or in combination with
one or more other substances. Product shall be deemed to include any “New Combination Product”, except (i) Net Sales of “New Combination Products” shall not be included in the calculation of First Tier Royalties and Second
Tier Royalties under Section 6.6.1, but instead shall be included in the calculation of royalties owing under Section 6.6.2, (ii) the Development Program shall not be deemed to include any activities concerning the New Combination
Product, (iii) for purposes of Article 2, Sections 1.30, 1.36, 1.51, 3.1, 3.2, 3.3, 3.4, 3.5, 4.2, 4.3, 4.4, 4.5, 4.6.1, 6.2, 6.2.1, 6.2.2, 6.4 and 6.5, (iv) NDAs and Approvals relating to any New Combination Product for territories
outside the United States may, Section 4.1.2 notwithstanding, be held in the name of any licensee or sublicensee of the Company, and (v) as otherwise provided for in the definition of “Net Sales” for purposes of calculating
royalties for Combination Products, provided that (a) the Company shall periodically, and at least quarterly, provide CDC with summary reports regarding activities undertaken by or on behalf of Company with respect to the development of any New
Combination Product (including studies/trials undertaken by the Company, the outcome and progress of such studies, and major outcomes and findings), so as to keep CDC fully advised of Company’s material development activities with respect to
New Combination Products and (b) “Program Data” shall, notwithstanding anything to the contrary, be deemed to include, in addition to all data, information, reports, results and other work product included in the definition thereof
under Section 5.1, all data, information, reports, results and other work product resulting from any clinical program and studies and associated support activities (including, without limitation, all specific protocol changes and other details
of the clinical programs, studies and support activities) conducted by or on behalf of Company to obtain and/or maintain Approval, including, without limitation, Approval from the FDA, with respect to any Product (including but not limited to any
New Combination Product).” 
 “Net Sales” means the gross amounts billed or invoiced by Company and its Affiliates,
sublicensees and distributors, and each of their successors and assigns, for sales of the Products (including New Combination Products) throughout the world, less the following deductions to the extent included in the gross invoiced sales price:

 (a) bona fide discounts (including but not limited to cash discounts, trade discounts, quantity discounts, and prompt
payment discounts), credits, rebates, refunds, allowances, cost of free goods, adjustments, rejections, recalls and returns, including rebates, refunds, allowances, or credits granted with respect thereto, and charge-back payments granted to managed
health care organizations or to Governmental Authorities, their agencies, and purchasers and reimbursers or to trade customers, including but not limited to wholesalers and chain and pharmacy buying groups, provided that such items relate to the
Product and only the portion of such items related to the Product shall be deducted; and 
 (b) taxes, tariffs and similar
obligations, duties or other governmental charges (other than income or corporation taxes) levied on, absorbed or otherwise imposed on sales of the Product; 

 If any such sales to third parties are made in transactions that are not at arm’s
length between the buyer and the seller, then the gross amount to be included in the calculation of Net Sales shall be the amount that would have been invoiced had the transaction been conducted at arm’s length, subject to deductions set forth
in subparagraphs (a) and (b) above. Such amount that would have been invoiced shall be determined, wherever possible, by reference to the average selling price of the relevant Product in arm’s-length transactions in such country.
Notwithstanding the foregoing, amounts received by Company or its Affiliates, sublicensees or distributors for the sale of Products among Company and its Affiliates, sublicensees or distributors for resale shall not be included in the computation of
Net Sales hereunder. Net Sales shall be determined from books and records maintained in accordance with GAAP, consistently applied throughout the organization and across all products of the entity whose sales of Product are giving rise to Net Sales.

 Net Sales of a Combination Product (as defined below), other than a New Combination Product, shall be calculated as if the
invoiced sales price for a Product included within the Combination Product is (i) the average sales price at which Company, its Affiliate, or a sublicensee or distributor thereof sells, in the calendar quarter of the applicable sale, the
Product alone and not as a part of the Combination Product in the applicable country or, if the Product is not offered in a country except as part of the Combination Product, the average sales price at which the Product is sold alone across all
countries in which such Product is sold, or (ii) to the extent the applicable Product has not been sold other than in a Combination Product, the amount reasonably specified between Company or its Affiliate, sublicensee, or distributor and any
other party to an agreement regarding that Combination Product as the portion of the sales price attributable to the Product. In the event that Company includes a Product as part of a single bundled sale of separate products with separately stated
prices, the Net Sales attributable to such Product shall be the higher of (i) the separately stated price stated for such Product sold in such bundled sale or (ii) the average price at which such Product is sold in the applicable country
in a non-bundled sale or, if not sold in the applicable country in a non-bundled sale, the average price at which such Product is sold in a non-bundled sale across all countries in which such Product is sold. For purposes of this paragraph,
“Combination Product” means a Product (other than a New Combination Product) that is sold together with any other products and/or services at a unit price, whether packaged together or separately with another pharmaceutical product or
other device, equipment, instrumentation, or other components (other than solely containers or packaging exclusively for the Product).” 
 (b) Added Definition. The following defined term shall be added as Section 1.68 of the CDC License, to read in its entirety as follows: 

“Generic Product” means a pharmaceutical product that (i) is not sold by BDSI, its Affiliates, or, under a license from BDSI, its
sublicensees or is not otherwise authorized by BDSI to be sold by any such entity, (ii) contains fentanyl and is administered in a transmucosal formulation; and (iii) has obtained Approval under 21 U.S.C. 505(j) (or any successor
legislation or similar legislation for approval of a generic product).” 
 “New Combination Product” means a
pharmaceutical product that (i) contains *** as the sole active ingredients and (ii) is administered in a transmucosal formulation utilizing the BEMA Technology. 

 “Onsolis” means the pharmaceutical product known as fentanyl buccal soluble film, having an
NDA# 22 266. 
 (c) Section 6.6.1 Royalties. Section 6.6.1 of the CDC License is hereby amended and restated in
its entirety to read as follows: 
 “6.6.1 Royalties on Net Sales. Commencing in the calendar year in which the
Product is sold, Company will pay to CDC, on a quarterly basis, a royalty on worldwide annual Net Sales of Products as follows: 
 (i) a *** royalty (the “First Tier Royalty”) on the first *** of worldwide Net Sales of Products in a particular calendar year. 

(ii) a *** royalty (the “Second Tier Royalty”) on the worldwide Net Sales of Products in a particular
calendar year exceeding the first *** of worldwide annual Net Sales of Products in a particular calendar year. 
 Notwithstanding
anything to the contrary, no royalties shall be due under this Section 6.6.1 on Net Sales of New Combination Products.” 
 (d) Deletion of Sections and Addition of New Section. Sections 6.6.2, 6.6.3, 6.6.4, 6.6.5 and 6.6.6 of the CDC License shall be amended and restated to read in their entirety as follows:

 “6.6.2 Royalties on Net Sales of New Combination Product. Commencing in the calendar year in which any New
Combination Product is sold, Company will pay to CDC, on a quarterly basis, a royalty on worldwide annual Net Sales of New Combination Products as follows: 
 (i) a *** (the “First Tier Royalty for New Combination Products”) on the first *** of worldwide Net Sales of New Combination Products in a particular calendar
year. 
 (ii) a *** royalty (the “Second Tier Royalty for New Combination Products”) on the
worldwide Net Sales of New Combination Products in a particular calendar year exceeding the first *** of worldwide Net Sales of New Combination Products in a particular calendar year.” 

“6.6.3 Minimum Royalty. Notwithstanding Sections 6.6.1 and 6.6.2, commencing on the Minimum Royalty Commencement Date, the
royalty payments made by Company to CDC pursuant to Sections 6.6.1 and 6.6.2 (if any) in any given calendar quarter shall not be less than Three Hundred Seventy-Five Thousand Dollars ($375,000) and in the event that the aggregate royalty payments in
any give calendar quarter as calculated pursuant to Sections 6.6.1 and 6.6.2 are less than Three Hundred Seventy-Five Thousand Dollars ($375,000), Company shall pay to CDC an amount equal to the difference between Three Hundred Seventy-Five Thousand
Dollars ($375,000) and the aggregate royalty payments previously paid to CDC for such calendar quarter (the “Shortfall Amount”), which Shortfall Amount payment shall be made to CDC at the time the royalty payment for such calendar quarter
is paid to CDC pursuant to the terms of Section 6.6.6. 

 “6.6.4 Launch of Combination Product. If a “New Combination Product”
receives Approval in a particular country for an indication that is the same or substantially similar as an indication for which Onsolis has received (regardless of whether the Approval for Onsolis has subsequently been withdrawn) Approval in such
country (such New Combination Product, a “Second Generation Combination Product”), then, notwithstanding anything to the contrary contained herein, from (and including) the calendar quarter following Approval of such New Combination
Product for such indication in such country until the later of (i) the earlier of (a) expiration of the last applicable BEMA Technology Patent Right covering Onsolis in such country or (b) July 1, 2018 or (ii) the first day
of the calendar quarter following the calendar quarter during which Generic Products have prescriptions filled for them in such country that exceed the number of prescriptions filled for Onsolis in such country, royalties on Net Sales of such Second
Generation Combination Product in such country shall, for every calendar quarter of such period during which Approvals for such indication for both Onsolis and such Second Generation Combination Product are in effect in such country, be calculated
in accordance with Section 6.6.1 and not 6.6.2; provided, however, that Net Sales in such country shall be determined as if such Second Generation Combination Product was a single Product and not a Combination Product. 

6.6.5 Intentionally Omitted. 
 6.6.6 “Timing of Payments. All amounts due CDC pursuant to this Section 6.6. shall be payable quarterly in arrears and such payments shall be made by Company to CDC within sixty
(60) days after March 31, June 30, September 30 and December 31 of each year. Each quarterly payment shall be accompanied by a written statement of royalties as described in Section 6.6.7.” 

(e) Section 6.6.8 Royalty Term. Section 6.6.8 of the CDC License is hereby amended and restated to read in its entirety
as follows: 
 “On a country-by-country and Product-by-Product basis, the royalty obligation of the Company under this
Agreement shall expire on the later of: (i) expiration of the last applicable BEMA Technology Patent Right covering a particular Product in a particular country; or (ii) the first full calendar year following the calendar year in which
generic versions of a particular Product have prescriptions filled for them in a particular country that exceed the number of prescriptions filled for the branded versions of such Product sold by or on behalf of Company, its Affiliates, or
sublicensees or distributors of any of the foregoing in such country in such calendar year. For purposes of Section 6.6.8, a “generic version” shall not include an “authorized generic” or any pharmaceutical product sold by
or on behalf of BDSI, its Affiliates, or sublicensees or distributors with respect to, in either case, the relevant Product.” 
 2. The parties acknowledge and agree that notwithstanding the royalty rates set forth in Section 6.6.1 above, since the commencement of Product sales, Company has been paying a royalty rate of
***% (the “Original First Tier Royalty Amount”) on sales of Product. As a result of paying royalties at the Original First Tier Royalty Amount, Company hereby acknowledges and agrees that, based on the royalty reports
provided by the Company, as of December 31, 2010, Company owes CDC and Athyrium the aggregate sum of $284,585 (the “Owed Royalty Amount”), without any setoff, counter claims or other deductions. Such Owed Royalty Amount shall be paid
simultaneously with the execution of this Amendment, by wire transfer of immediately available funds to an account designated in writing by CDC and Athyrium. The parties further agree that Company shall immediately commence paying the royalties on
Products, other than New Combination Products, at a rate equal to the First Tier Royalty or Second Tier Royalty, as applicable. 

 3. Except as expressly amended hereby, the CDC License shall continue in full force and
effect in accordance with the provisions thereof on the date hereof. As used in the CDC License, the terms “Agreement”, “this Agreement”, “herein”, “hereafter”, “hereto”, “hereof”, and
words of similar import, shall, unless the context otherwise requires, mean the CDC License as amended, including as amended by this Amendment. To the extent there is any conflict between the CDC License and this Amendment, the terms of this
Amendment shall prevail. 
 4. APPLICABLE LAW. THIS AMENDMENT SHALL BE GOVERNED BY AND INTERPRETED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ITS CONFLICTS OF LAWS RULES. 
 5. This Amendment may be executed in any number
of counterparts, each such counterpart shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement. Any such counterpart may contain one or more signature pages. Any and all counterparts may be
executed by facsimile. 
 6. The headings of this Amendment are for the purposes of reference only and shall not affect the
construction of or be taken into consideration in interpreting this Amendment. 
 [No Further Text on This Page] 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***”

 IN WITNESS WHEREOF, the undersigned parties have executed this Amendment as of the date set forth in the first
paragraph hereof. 
  

			
	CDC V, LLC
		
	By:	 	 /s/ David R.
Ramsay

			
	Name:	 	David R. Ramsay
	Title:	 	Authorized Signatory
	
	NB ATHYRIUM LLC
	
	By its managing member, NB SOF II HOLDINGS (D) LP
	
	By its general partner, NB SECONDARY OPPORTUNITIES ASSOCIATES II LP
	
	By its general partner, NB SECONDARY OPPORTUNITIES ASSOCIATES II GP LLC

			
		
	By:	 	 Christian
Neira

			
	Name:	 	Christian Neira
	Title:	 	Authorized Signatory
	
	BIODELIVERY SCIENCES INTERNATIONAL, INC.:

			
		
	By:	 	 Mark A.
Sirgo

			
	Name:	 	Mark A. Sirgo
	Title:	 	President and CEO

 
			
	ARIUS PHARMACEUTICALS, INC.:
		
	By:	 	 Mark A.
Sirgo

			
	Name:	 	Mark A. Sirgo
	Title:	 	President and CEO
	
	ARIUS TWO, INC.:

			
		
	By:	 	 Mark A.
Sirgo

			
	Name:	 	Mark A. Sirgo
	Title:	 	President and CEOExecutive Employment Agreement

 Exhibit 10.32 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 This Executive Employment Agreement
(“Agreement”) is entered into as of March 1, 2010 (“Effective Date”), by Osmetech Technology, Inc. and subsidiaries (“Company”) and Jeffrey Hawkins (“Executive”). Company and Executive are each a
“Party” to this Agreement and are sometimes collectively referred to as “Parties.” This Agreement supersedes any previous written or verbal agreements. 
 Recitals Of The Intent Of The Parties 
 A. The Company wishes to
employ Executive, and Executive wishes to accept such employment. 
 B. Executive acknowledges that this Agreement is necessary
for the protection of Company’s investment in its business, goodwill, products, services, methods of operation, information, and relationships with its customers and other employees; and 

C. Company acknowledges that Executive desires definition of the compensation and benefits, and other terms of employment; 

Agreement Of The Parties 
 In consideration of foregoing recitals, the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is
acknowledged, the Company and Executive agree as follows: 
 1. Employment. Company employs Executive, and
Executive agrees to be employed by Company, upon the terms and conditions set forth in this Agreement beginning on the Effective Date and continuing until terminated by either Party pursuant to the terms of this Agreement. 

2. Duties. 
 2.1. Basic Duties. Executive agrees to serve as Vice President of Business Development, reporting to the Chief Executive Officer and with such other powers, duties and responsibilities usually
vested in his position as well as additional or different duties that Executive may be reasonably directed to perform by Company. 
 2.2. Time Devoted to Employment. Executive will devote his full time to the business of Company during the term of this Agreement and will perform his duties and responsibilities faithfully,
diligently and to the best of his ability, in compliance with all applicable laws and the Company’s policies and procedures. Executive will not engage in any other business activity, except as may be approved in writing by the Chief Executive
Officer of Company, in its sole discretion. 
 2.3. Place of Performance. Executive shall be based at Company’s
offices in Pasadena, California until such time as the Company relocates to the San Diego Area. The Executive will be required to travel on Company’s business from time-to-time. 

2.4. No Conflicting Agreements. Executive represents and warrants that the performance of Executive’s duties under this
Agreement does not and will not breach any other agreement, including any confidentiality and non-disclosure agreements with prior employers or other 

 
 CONFIDENTIAL 

 
persons. Executive represents and warrants that Executive has not entered into, and will not enter into, any agreement, either written or oral in conflict with this Agreement. Executive
represents that Executive has disclosed to Company any actual or potential conflicts. 
 2.5. Duty of Loyalty. Executive
acknowledges and agrees that Executive owes a fiduciary duty of loyalty, fidelity and allegiance to act at all times in the best interests of the Company and to do no act which would intentionally injure Company’s business, its interests, or
its reputation. Executive understands that it is Company’s policy to conduct its business ethically and legally and agrees to uphold those standards of business conduct and ethical principles, and comply with all applicable laws and regulations
and Company’s policies. 
 3. Compensation and Method of Payment. 

3.1. Total Compensation. As compensation under this Agreement, Company will pay and Executive will accept the following:

 3.1.1. Executive will receive on an annual basis of One Hundred Ninety Thousand Dollars ($190,000.00) (“Base
Salary”). The Company will review Executive’s Base Salary annually and may, in its sole discretion increase the Executive’s Base Salary, considering Executive’s achievements during the prior period, business conditions and other
factors as may be deemed relevant by Company. 
 3.1.2. Executive will be eligible to participate in the Management Incentive
Bonus of up to 25% variable pay based on current base salary, which will be defined on an annual basis and requires approval by the Board of Directors. Executive will only earn and be entitled to a Management Incentive Bonus if Executive is employed
on the date the bonus is payable and Company will not pay prorated Management Incentive Bonus in the event of Executives earlier departure. 
 3.1.3. The Company will also offer Executive participation in the OMD stock incentive program. Executive has been granted 9,800,660 options to purchase shares of Osmetech Stock per the current plan
policies and procedures which included Board of Directors’ approval. 
 3.1.4. The Company will assist
Executive with relocation costs in the amount of $70,000.00 (less all applicable local, state and federal taxes) to be applied to such things as house hunting trips, moving of household items, home sale closing costs, etc. This assistants will be
paid in two installments. One half ($35,000), to be paid at Executive’s request. The second portion ($35,000) will be paid upon completion of relocation in the form of a signed escrow agreement on a new home within San Diego County, no later
than September 30th, 2010. 

3.1.5. Company will reimburse Executive for all reasonable travel, entertainment and other expenses incurred or paid by Executive in
connection with the performance of Executive’s duties, responsibilities or services under this Agreement, upon presentation by the Executive of documentation as Company may request and in accordance with any applicable policies adopted by the
Company. 
 3.1.6. Executive will be entitled to participate in employee fringe benefit, health insurance, life insurance, and
other programs which Company may adopt from time to time for executives of Company. Participation will be in accordance with any plans and any applicable policies adopted by Company. Executive will be entitled to accrue 15 days (120 hours) of
vacation in accordance with Company policy in effect from time to time and subject to applicable state law. 

  
 2 

 CONFIDENTIAL 

 3.2. Reservation of Rights. Notwithstanding any other provision of this Agreement,
Company reserves the right to modify, suspend or discontinue any and all benefit plans, practices, policies and programs at any time whether before or after termination of employment without advance notice to or recourse by Executive. 

3.3. Payment of Compensation. The Company will pay Executive’s Base Salary in accordance with the normal payroll cycle of the
Company as established from time to time. All compensation paid to Executive will be subject to applicable taxes, withholding and other required, usual or elected employee deductions. 

4. Termination of Agreement. 
 This Agreement and all obligations under this Agreement (except for obligations contained in Sections 4, 5 and 6, which will survive any termination of Executive’s employment or this Agreement) will
terminate upon the earliest to occur of any of the following: 
 4.1. At-Will. Either Party may terminate
Executive’s employment for any reason, with or without cause and without advance notice. 
 4.1.1. If Executive terminates
employment pursuant to this Section, Executive will receive (a) Base Salary prorated through the last day of Executive’s actual employment; (b) any bonus, if earned pursuant to the requirements of Section 3; (c) accrued and
unpaid vacation; (d) unreimbursed expenses pursuant to Section 3 (collectively, “Separation Pay”). Except to the extent required by law or Incentive Plan Document, all other obligations and liabilities of Company terminate as of
the effective date of any such termination. 
 4.2. Death or Disability. This Agreement will terminate immediately upon
the death of Executive or upon the determination that Executive cannot perform the fundamental duties of his position with or without accommodation. If this Agreement terminates for the death or disability of Executive, Executive or Executive’s
representatives will receive Separation Pay. Except to the extent required by law or Incentive Plan Document, all other obligations and liabilities of Company terminate as of the effective date of any such termination. 

4.3. Compliance with IRC Section 409A. Notwithstanding anything to the contrary in this Agreement, if any payment to be made
pursuant to this Agreement will trigger any accelerated or additional tax under Section 409A, then Company will defer or modify the commencement or payments to prevent such accelerated or additional tax under Section 409A. 

4.4. Resignation as Board Member or Officer. If applicable to Executive, immediately upon the termination of Executive’s
employment with Company, Executive will tender a written notice of Executive’s resignation from any and all offices of the Company and all subsidiaries, affiliates or clients in which the Executive represents the Company in the capacity of an
officer or director. Notwithstanding any failure by the Executive to provide the Company with written notice of resignation, Executive hereby authorizes and directs the Board of Directors to accept the Executive’s resignation from all positions
effective as of the date of termination of the Executive’s employment. 
 5. Property Rights and Obligations of
Executive. Executive agrees to be bound by the terms and conditions of Company’s Employee Non-Disclosure and Invention Agreement, which is 

  
 3 

 CONFIDENTIAL 

 incorporated by reference and attached as an Exhibit A to this Agreement. The provisions of this
Section 5 and Attachment A will survive the termination of this Agreement. The covenants in this Section 5 and Attachment A will be construed as separate covenants and to the extent any covenant will be judicially unenforceable, it will not
affect the enforcement of any other covenant. In the event Executive breaches any of the provisions of this Section 5 and Attachment A, Executive agrees that Company will be entitled to injunctive relief in addition to any other remedy to which
Company may be entitled. 
 6. General Provisions. 

6.1. Notices. Any notices or other communications required or permitted to be given under this Agreement must be in writing and
addressed to Company or Executive at the addresses below, or at such other address as either Party may from time to time designate in writing. Any notice or communication that is addressed as provided in this Section will be deemed given
(a) upon delivery, if delivered personally or via certified mail, postage prepaid, return receipt requested; or (b) on the first business day of the receiving Party after the transmission if by facsimile or after the timely delivery to the
courier, if delivered by overnight courier. Other methods of delivery will be acceptable only upon proof of receipt by the Party to whom notice is delivered. 
  

					
	 If to Company:
	 		  	Osmetech Molecular Diagnostics, 757 S. Raymond Ave, Pasadena, Ca 91105 ATTN: Human Resources
			
	 If to Executive:
	 		  	331 Ridgewood Ave, Glen Ellyn, IL 60137

6.2. Choice of Law and Forum. Except as expressly provided otherwise in this Agreement, this Agreement will be governed by and
construed in accordance with the laws of the State of California. Both Parties agree that San Diego, California will be the venue of any proceeding and both Parties consent to the personal jurisdiction of the state and federal courts of the State of
California. 
 6.3. Entire Agreement; Modification and Waiver. This Agreement supersedes any and all other agreements,
whether oral or in writing, between the Parties with respect to the employment of Executive by Company and contains all covenants and agreements between the Parties relating to such employment in any manner whatsoever. Each Party to this Agreement
acknowledges that no representations, inducements, promises, or agreements, oral or written, have been made by any Party, or anyone acting on behalf of any Party, that are not embodied herein, and that no other agreement, statement, or promise not
contained in this Agreement will be valid or binding. Any modification of this Agreement will be effective only if it is in writing signed by the Party to be charged. No waiver of any of the provisions of this Agreement will be deemed, or will
constitute, a waiver of any other provision, whether or not similar, nor will any waiver constitute a continuing waiver. No waiver will be binding unless executed in writing by the Party making the waiver. 

6.4. Assignment. This Agreement may not be assigned in whole or in part by Executive without the prior written consent of Company.
However, subject to the foregoing limitation, this Agreement will be binding on, and will inure to the benefit of, the Parties and their respective heirs, legatees, executors, administrators, legal representatives, successors and assigns.

  
 4 

 CONFIDENTIAL 

 6.5. Severability. If for any reason whatsoever, any one or more of the provisions of
this Agreement will be held or deemed to be inoperative, unenforceable, or invalid as applied to any particular case or in all cases, such circumstances will not have the effect of rendering any such provision inoperative, unenforceable, or invalid
in any other case or of rendering any of the other provisions of this Agreement inoperative, unenforceable or invalid. 
 6.6.
Representation by Counsel; Interpretation. Company and Executive acknowledge that each Party to this Agreement has had the opportunity to be represented by counsel in connection with this Agreement and the matters contemplated by this
Agreement. Accordingly, any rule of law or decision which would require interpretation of any claimed ambiguities in this Agreement against the Party that drafted it has no application and is expressly waived. In addition, the term
“including” and its variations are always used in the non-restrictive sense (as if followed by a phrase such as “but not limited to”). The provisions of this Agreement will be interpreted in a reasonable manner to affect the
intent of the Parties. 
 6.7. Headings and Captions. Headings and captions are included for purposes of convenience only
and are not a part of the Agreement. 
 6.8. Counterparts. This Agreement may be executed simultaneously in one or more
counterparts, each of, which will be deemed an original, but all of which together will constitute one and the same instrument. Fax signatures will be valid and binding. 

 

			
	OSMETECH MOLECULAR DIAGNOSTICS
		
	By:	 	 /s/Jon Faiz Kayyem

	Its:	 	Chief Executive Officer
		
	Date:	 	3/10/10
	
	“Executive”
	
	 /s/Jeffrey A. Hawkins

	Jeffrey A. Hawkins
		
	Date:	 	3/10/10

  
 5 

 CONFIDENTIAL 

 Attachment A to Executive Employment Agreement 

Employee Non-Disclosure and Invention Agreement 
 This Executive Non-Disclosure and Invention Agreement (“NDIA Agreement”) is entered into as of the Effective Date of the Executive Employment Agreement (“NDIA Agreement”) Osmetech
Molecular Diagnostics, a wholly owned subsidiary of Osmetech Technologies, Inc. (“Company”) and Jeffrey A. Hawkins (“Executive”). Company and Executive are each a “Party” to this NDIA Agreement and are sometimes
collectively referred to as “Parties.” 
 Recitals Of The Intent Of The Parties 

A. As an employee of the Company, Executive may receive or have access to business plans, inventions, discoveries, technical information,
trade secrets, writings, designs, and other proprietary and confidential information of value and of such importance to the Company that it must be maintained as proprietary and confidential trade secrets of the Company both during and after
termination of your employment. Furthermore, Executive may conceive or create Inventions (as defined below) in connection with and during the period of Executive’s employment with the Company. 

B. This NDIA Agreement is attached to and incorporated into the Agreement pursuant to Section 5 of the Agreement. Execution of this
NDIA Agreement is a condition of employment. 
 In consideration for the new or continued employment of Executive, and other
valuable consideration, Company and Executive agree as follows: 
 1. NON-DISCLOSURE OF CONFIDENTIAL INFORMATION.
Executive recognizes that during the course of employment with Company, Executive may have access to Confidential Information of Company, its subsidiaries and other organizations controlled by, controlling, or under common control with it
(“Affiliates”). “Company Group” means Osmetech, Inc. and its Affiliates, including Company. Company Group is a third-party beneficiary of this NDIA Agreement and the restrictive covenants in this NDIA Agreement are intended for
the benefit of Company Group. As used in this NDIA Agreement, the term “Confidential Information” means the applicable information of each Company Group and includes information not publicly available about Company Group’s:
(a) research and development; manufacturing methods and formulas; (b) purchasing; marketing; sales costs; pricing inventions; improvements; (c) inventions, discoveries and ideas (whether patentable or not) related to their activities;
(d) business and management development plans; (e) customer and supplier contact information and requirements; (f) proprietary software systems and technology related methodologies; (g) customers’ proprietary software
systems and technology related methodologies; (h) activities of their established committees or boards; (i) litigation, disputes, or investigations to which they may be (or may have been) a party and legal advice provided to Executive in
the course of Executive’s employment; and (j) any other trade secrets. Executive acknowledges and agrees that all rights, title and interest in any Confidential Information will remain the exclusive property of Company. Executive will not,
without the written consent of the Chief Operating Officer, during the term employment or at any time after the termination of employment, disclose copy, make use of, or remove from Company premises, Confidential Information except as may be
required in the course of Executive’s employment with and for the 

  
 6 

 CONFIDENTIAL 

 
benefit of Company. Executive specifically acknowledges that any use of Confidential Information by persons not employed by Company or who are not authorized by Company to use the information
provides such persons an unfair competitive advantage which they would not have had without the use of Confidential Information. 
 2. RETURN OF CONFIDENTIAL INFORMATION AND OTHER COMPANY PROPERTY. No later than Executive’s termination date, Executive will return to Company and delete from any personal computer or other
device all originals and all copies of any Company property, Confidential Information, and all materials, documents, notes, manuals, computer disks, computers, or lists containing or embodying Confidential Information, or relating directly or
indirectly to the business of Company, which are in Executive’s possession or control. 
 2.1.
INVENTIONS AND ORIGINAL WORKS ASSIGNED TO Company. Executive agrees to make prompt written disclosure to Company, will hold in trust for the sole right and benefit of Company, and hereby assigns to Company all Executive’s right, title
and interest in and to any ideas, inventions, discoveries, concepts and ideas, whether patentable or not, including but not limited to processes, methods, formulae, software, techniques, strains, cultures, and organisms, as well as improvements and
know-how, concerning any present or planned activities of Company that Executive is aware of as a result of employment of Company, original works of authorship, developments, improvements or trade secrets which Executive may solely or jointly
conceive or reduce to practice, or cause to be conceived or reduced to practice, during the period of Executive’s employment with Company. Executive recognizes that this NDIA Agreement does not require assignment of any invention, which
qualifies for protection under Section 2870 of the California Labor Code. 1 
 3. In addition, Executive acknowledges that all original works of authorship
which are made by Executive (solely or jointly with others) within the scope of employment and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act. Executive will assist
to obtain and enforce United States and foreign proprietary rights relating to any and all inventions, original works of authorship, developments, improvements or trade secrets of Company. 

4. INVENTIONS/ORIGINAL WORKS RETAINED BY EMPLOYEE. Below is a complete disclosure of all inventions, original works of authorship,
developments, improvements, and trade secrets that he has, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of Executive’s employment
with Company, that Executive considers to be the property of Executive or the property of third parties and that Executive wishes to have excluded from the scope of this NDIA Agreement:
                                         
                                   . 

 
  

	1 	 Section 2870 provides: (a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of
his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information
except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or
(2) Result from any work performed by the employee for the employer. (b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned
under subdivision (a), the provision is against the public policy of this state and is unenforceable. 

  
 7 

 CONFIDENTIAL 

 5. NOTICE TO THIRD PARTIES. In the event that Executive’s employment with
Company terminates, Executive consents to the notification of Executive’s new employer or company of Executive’s rights and obligations under this NDIA Agreement. 
 6. OBLIGATIONS TO FORMER EMPLOYERS AND OTHER PARTIES. Executive promises that Executive has not brought to Company and will not improperly use or disclose any proprietary information or trade
secret of former employers or companies. Executive also represents that Executive’s employment under this NDIA Agreement does not breach any other agreement or obligation of Executive and that Executive has not entered into any written or oral
agreement in conflict with this NDIA Agreement. 
 7. NON-SOLICITATION OF COMPANY EMPLOYEES. Executive recognizes that
Company’s employees are a valuable resource of Company. Executive will not during the term of Executive’s employment and for a period of one (1) year following its termination, either alone or in conjunction with any other person or
entity, directly or indirectly solicit, induce, recruit, aid or suggest to any Company Executive to leave the employ of Company, or terminate or violate any contractual or fiduciary duty owing to Company. 

8. RESTRICTIONS ON COMPETITION DURING EMPLOYMENT. Executive agrees that during Executive’s employment with Company Executive
will not, directly or indirectly, have any ownership interest, work for advise, or have any business relationship with any person or entity that competes with Company, or that is planning to compete with Company, without the prior written approval
of a manager who is at least at the Vice President level. While employed by Company, Executive will not use any unfair business practices to establish a competing business or undertake any actions to impair Company’s relationship with its
existing customers and business. 
 9. NON-SOLICITATION OF CUSTOMERS USING CONFIDENTIAL INFORMATION. Executive recognizes
that information about Company’s customers are Confidential Information and trade secrets of Company. During the term of Executive’s employment and for a period of one (1) year following its termination, Executive will not use
Confidential Information or other unfair business practices to divert or attempt to divert from Company any business or customers with whom Executive dealt or about whom Executive had access to Confidential Information by virtue of Executive’s
employment. 
 10. SURVIVAL OF OBLIGATION. Executive expressly understands and agrees that the obligations,
responsibilities and duties of Executive under this NDIA Agreement will survive the termination of Executive’s employment with Company. 
 11. NOTICE OF LEGAL OBLIGATION. In the event that Executive is required in a civil, criminal or regulatory proceeding to disclose any part of the Confidential Information, Executive will give the
President of Company prompt written notice of the request to permit Company to seek an appropriate remedy or to waive the Executive’s compliance with the provisions of this NDIA Agreement in regard to the request. 

12. NOTICE OF UNAUTHORIZED DISCLOSURE. If Executive loses or makes unauthorized disclosure of any of the Confidential Information,
the Executive will immediately notify Company take all reasonable steps necessary to retrieve the lost or improperly disclosed Confidential Information. 

  
 8 

 CONFIDENTIAL 

 13. EMPLOYMENT AT-WILL. Nothing in this NDIA Agreement is intended to change the
at-will status of Executive’s employment with Company and Executive understands that Company or Executive may terminate the employment relationship with or without cause and with or without advance notice. 

14. REMEDIES. The parties recognize that a breach of this NDIA Agreement by Executive will cause an irreparable injury to Company
that cannot be reasonably or adequately compensated for in money damages. In the event of any breach or threatened breach, Company will be entitled, in addition to any other remedies and damages available, to an injunction to restrain such breach or
threatened breach by Executive, Executive’s partners, co-employees, agents, employers and employees, and any other persons acting or with Executive. Company will be entitled to injunctive relief for the duration specified in the applicable
paragraph(s) of the NDIA Agreement, commencing from the date such relief is granted, but reduced by the period of time elapsed between Executive’s termination date and Executive’s first breach or threatened breach of this NDIA Agreement.

 15. ASSIGNMENT. This NDIA Agreement will be binding upon and inure to the benefit of Company, its successors and
assigns, and to the benefit of Executive, Executive’s heirs and legal representatives. Executive agrees that this NDIA Agreement may be assigned by Company to any successor or other party, without the consent of Executive. The transfer of
Executive to any other Company corporate parent, affiliate, subsidiary, or successor will constitute an assignment of this NDIA Agreement. 
 16. CONTROLLING LAW AND JURISDICTION. This NDIA Agreement will be governed by, construed by, and enforced in accordance with the laws of the State of California without regard to conflict of law
provisions. Executive specifically consents to personal jurisdiction in the State of California. 
 17. SEVERABILITY. If
any provision, paragraph or subparagraph in this NDIA Agreement is adjudged by any court to be void or unenforceable in whole or in part, this adjudication will not affect the validity of the remainder of the NDIA Agreement. Each provision,
paragraph and subparagraph of this NDIA Agreement is separable and constitutes a separate and distinct covenant. The parties further expressly agree that if any provision is susceptible to two or more constructions, one of which would render the
provision unenforceable, then the provision will be construed to have the meaning that renders it enforceable. 
 18.
HEADINGS AND INTERPRETATION. Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this NDIA Agreement. Words in the singular mean and include the plural and vice versa. Words in the
masculine mean and include the feminine and vice versa. The term “including” and its variations are always used in the non-restrictive sense as if followed by a phrase such as “but not limited to. Executive and Company agree that any
ambiguity in the terms of this NDIA Agreement will not be construed against any of the parties and any rule of law or decision that would require interpretation of any claimed ambiguities in this NDIA Agreement against the party that drafted it is
expressly waived. The provisions of this NDIA Agreement will be interpreted in a reasonable manner to affect the intent of the parties. 
 19. AMENDMENT AND NONWAIVER. This NDIA Agreement may only be amended or modified by a written instrument executed by both Company and Executive. The failure by Company to enforce any provision of
this NDIA Agreement will not be deemed a waiver of such provision or of Company’s right to enforce each and every provision of this NDIA Agreement, or agreements signed by other employees. Any such failure will not operate or be construed as a
waiver of any subsequent breach by Executive. 

  
 9 

 CONFIDENTIAL 

 20. COUNTERPARTS. This NDIA Agreement may be executed in counterparts and a faxed
signature will be valid. 
 21. ENTIRE AGREEMENT. This NDIA Agreement constitutes the entire agreement of the parties
with respect to the subject matter of the NDIA Agreement and supersedes and replaces any previous communications, representations, arrangements or agreements, whether oral or written, addressing the terms, conditions, and issues contained in the
NDIA Agreement. 
  

			
	OSMETECH MOLECULAR DIAGNOSTICS
		
	By:	 	 /s/Jon Faiz Kayyem

	Its:	 	Chief Executive Officer
		
	Date:	 	3/10/10
	
	“Executive”
	
	 /s/Jeffrey A. Hawkins

	Jeffrey A. Hawkins
		
	Date:	 	3/10/10

  
 10 

 CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]